This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Troels Koch, PhD
Senior Vice President, Chemistry at MiNa Therapeutics


Troels Koch is Senior Vice President Chemistry at MiNA Therapeutics. TK has 20 years’ experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most known. Santaris Pharma A/S was acquired by Roche in August 2014 - and Exiqon A/S was in 2016 acquired by Qiagen. TK pioneered LNA therapeutics and has positioned LNA antisense science and technology at an international lead position. TK has worked with RNA therapeutics for more than 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. TK has built R&D organizations up to 75 co-workers, held >100 invited presentations at international conferences and is author of 90 peer reviewed publications.

Agenda Sessions

  • Chairperson's Remarks